ClearPoint Neuro (CLPT) Financials

$12.82 +1.14 (+9.76%)

Closing price 04:00 PM Eastern

Extended Trading

$12.99 +0.17 (+1.33%)

As of 07:42 PM Eastern

Annual Income Statements for ClearPoint Neuro

This table shows ClearPoint Neuro's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-16	-22	-19
Consolidated Net Income / (Loss)	-16	-22	-19
Net Income / (Loss) Continuing Operations	-16	-22	-19
Total Pre-Tax Income	-16	-22	-19
Total Operating Income	-16	-22	-20
Total Gross Profit	14	14	19
Total Revenue	21	24	31
Operating Revenue	21	24	31
Total Cost of Revenue	7.02	10	12
Operating Cost of Revenue	7.02	10	12
Total Operating Expenses	30	36	39
Selling, General & Admin Expense	9.61	12	12
Marketing Expense	9.36	13	14
Research & Development Expense	11	12	12
Total Other Income / (Expense), net	-0.10	0.39	0.83
Interest Expense	0.08	-0.39	-0.87
Other Income / (Expense), net	-0.02	-	-0.04
Basic Earnings per Share	($0.68)	($0.90)	($0.70)
Weighted Average Basic Shares Outstanding	24.18M	24.61M	27.03M
Diluted Earnings per Share	($0.68)	($0.90)	($0.70)
Weighted Average Diluted Shares Outstanding	24.18M	24.61M	27.03M
Weighted Average Basic & Diluted Shares Outstanding	24.61M	26.98M	27.63M

This table shows ClearPoint Neuro's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-3.79	-4.39	-5.61	-7.05	-4.81	-4.62	-4.15	-4.41	-4.97	-5.39
Consolidated Net Income / (Loss)	-3.79	-4.39	-5.61	-7.05	-4.81	-4.62	-4.15	-4.41	-4.97	-5.39
Net Income / (Loss) Continuing Operations	-3.79	-4.39	-5.61	-7.05	-4.81	-4.62	-4.15	-4.41	-4.97	-5.39
Total Pre-Tax Income	-3.79	-4.39	-5.61	-7.05	-4.80	-4.60	-4.15	-4.41	-4.97	-5.39
Total Operating Income	-3.80	-4.47	-5.71	-7.13	-4.90	-4.71	-4.23	-4.74	-5.17	-5.60
Total Gross Profit	3.68	3.37	3.20	3.13	3.27	4.01	4.53	4.99	4.85	4.76
Total Revenue	5.15	5.17	5.43	5.95	5.76	6.81	7.64	7.86	8.12	7.77
Operating Revenue	5.15	5.17	5.43	5.95	5.76	6.81	7.64	7.86	8.12	7.77
Total Cost of Revenue	1.47	1.81	2.23	2.82	2.49	2.80	3.11	2.87	3.28	3.01
Operating Cost of Revenue	1.47	1.81	2.23	2.82	2.49	2.80	3.11	2.87	3.28	3.01
Total Operating Expenses	7.47	7.84	8.91	10	8.17	8.72	8.76	9.73	10	10
Selling, General & Admin Expense	2.40	2.38	2.96	3.18	2.90	2.72	2.84	2.77	3.16	3.23
Marketing Expense	2.42	2.53	2.93	3.47	2.84	3.35	3.29	3.83	3.55	3.81
Research & Development Expense	2.65	2.93	3.02	3.61	2.43	2.65	2.63	3.12	3.32	3.33
Total Other Income / (Expense), net	0.01	0.08	0.10	0.08	0.10	0.10	0.09	0.33	0.20	0.22
Interest Expense	-0.03	-0.08	-0.11	-0.08	-0.10	-0.09	-0.11	-0.33	-0.21	-0.23
Other Income / (Expense), net	-0.03	-	-0.01	-0.00	-	-	-0.03	0.01	-0.01	-0.01
Basic Earnings per Share	($0.15)	($0.18)	($0.23)	($0.29)	($0.20)	($0.18)	($0.16)	($0.16)	($0.18)	($0.20)
Weighted Average Basic Shares Outstanding	24.50M	24.18M	24.58M	24.58M	24.63M	24.61M	25.45M	27.47M	27.59M	27.03M
Diluted Earnings per Share	($0.15)	($0.18)	($0.23)	($0.29)	($0.20)	($0.18)	($0.16)	($0.16)	($0.18)	($0.20)
Weighted Average Diluted Shares Outstanding	24.50M	24.18M	24.58M	24.58M	24.63M	24.61M	25.45M	27.47M	27.59M	27.03M
Weighted Average Basic & Diluted Shares Outstanding	24.55M	24.61M	24.58M	24.64M	24.62M	26.98M	27.42M	27.60M	27.58M	27.63M

This table details how cash moves in and out of ClearPoint Neuro's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-26	-4.48	-3.04
Net Cash From Operating Activities	-16	-14	-8.95
Net Cash From Continuing Operating Activities	-16	-14	-8.95
Net Income / (Loss) Continuing Operations	-16	-22	-19
Consolidated Net Income / (Loss)	-16	-22	-19
Depreciation Expense	0.24	0.63	0.98
Amortization Expense	0.30	0.76	0.97
Non-Cash Adjustments To Reconcile Net Income	3.47	6.58	6.61
Changes in Operating Assets and Liabilities, net	-3.75	0.40	1.40
Net Cash From Investing Activities	-11	8.95	-0.28
Net Cash From Continuing Investing Activities	-11	8.95	-0.28
Purchase of Property, Plant & Equipment	-0.25	-0.72	-0.28
Acquisitions	-0.89	-0.33	0.00
Sale and/or Maturity of Investments	12	10	0.00
Net Cash From Financing Activities	0.41	0.30	6.19
Net Cash From Continuing Financing Activities	0.41	0.30	6.19
Repayment of Debt	-	0.00	-10
Issuance of Common Equity	0.48	0.51	17
Other Financing Activities, net	-0.07	-0.21	-0.40
Cash Interest Paid	0.52	0.74	0.48
Cash Income Taxes Paid	0.00	0.00	0.06

This table details how cash moves in and out of ClearPoint Neuro's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-4.81	8.90	-5.82	4.67	-2.12	-1.20	12	-2.51	-11	-1.47
Net Cash From Operating Activities	-3.85	-3.07	-5.68	-5.08	-1.80	-1.17	-3.84	-2.67	-1.20	-1.24
Net Cash From Continuing Operating Activities	-3.85	-3.07	-5.68	-5.08	-1.80	-1.17	-3.84	-2.67	-1.20	-1.24
Net Income / (Loss) Continuing Operations	-3.79	-4.39	-5.61	-7.05	-4.81	-4.62	-4.15	-4.41	-4.97	-5.39
Consolidated Net Income / (Loss)	-3.79	-4.39	-5.61	-7.05	-4.81	-4.62	-4.15	-4.41	-4.97	-5.39
Depreciation Expense	0.04	0.02	0.13	0.16	0.16	0.18	0.24	0.69	-0.20	0.24
Amortization Expense	0.01	0.02	0.09	0.14	0.28	0.26	0.25	-0.22	0.71	0.23
Non-Cash Adjustments To Reconcile Net Income	1.09	0.61	1.48	1.93	2.03	1.14	1.36	1.44	1.90	1.91
Changes in Operating Assets and Liabilities, net	-1.21	0.67	-1.77	-0.25	0.54	1.87	-1.54	-0.17	1.35	1.76
Net Cash From Investing Activities	-0.63	12	-0.14	9.51	-0.24	-0.19	0.00	-	-0.01	-0.26
Net Cash From Continuing Investing Activities	-0.63	12	-0.14	9.51	-0.24	-0.19	0.00	-	-0.01	-0.26
Purchase of Property, Plant & Equipment	-0.07	-0.04	-0.14	-0.32	-0.24	-0.02	0.00	-	-0.01	-0.26
Net Cash From Financing Activities	-0.33	0.22	-0.01	0.24	-0.09	0.16	16	0.16	-10	0.04
Net Cash From Continuing Financing Activities	-0.33	0.22	-0.01	0.24	-0.09	0.16	16	0.16	-10	0.04
Issuance of Common Equity	-	0.22	0.00	0.31	-	0.19	16	0.29	-	0.12
Other Financing Activities, net	-0.33	0.01	-0.01	-0.08	-0.09	-0.04	-0.13	-0.13	-0.06	-0.08
Cash Income Taxes Paid	-	-	0.00	-	-	-	0.00	-	-	0.06

This table presents ClearPoint Neuro's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	55	43	39
Total Current Assets	51	36	33
Cash & Equivalents	28	23	20
Short-Term Investments	9.87	0.00	0.00
Accounts Receivable	2.67	3.21	4.71
Inventories, net	9.30	7.91	6.86
Prepaid Expenses	1.72	1.91	1.68
Plant, Property, & Equipment, net	0.81	1.39	2.01
Total Noncurrent Assets	3.50	5.10	3.82
Intangible Assets	-	1.04	0.48
Other Noncurrent Operating Assets	3.50	4.06	3.34
Total Liabilities & Shareholders' Equity	55	43	39
Total Liabilities	19	21	14
Total Current Liabilities	6.79	7.43	10
Accounts Payable	0.27	0.39	1.34
Accrued Expenses	2.07	1.05	1.45
Current Deferred Revenue	1.07	2.61	2.12
Current Employee Benefit Liabilities	2.82	2.95	4.89
Other Current Liabilities	0.56	0.42	0.56
Total Noncurrent Liabilities	12	14	3.45
Long-Term Debt	9.89	9.95	0.00
Noncurrent Deferred Revenue	0.39	0.54	0.44
Other Noncurrent Operating Liabilities	1.53	3.57	3.01
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	37	21	25
Total Preferred & Common Equity	37	21	25
Preferred Stock	0.00	0.00	0.00
Total Common Equity	37	21	25
Common Stock	187	194	217
Retained Earnings	-150	-172	-191

This table presents ClearPoint Neuro's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	58	50	48	44	54	53	40
Total Current Assets	54	46	41	37	48	47	34
Cash & Equivalents	19	22	26	24	35	33	22
Accounts Receivable	3.41	2.68	2.80	2.42	2.51	3.48	3.88
Inventories, net	8.28	9.81	9.20	8.99	7.96	8.03	7.06
Prepaid Expenses	1.66	1.76	2.24	1.56	1.75	2.21	1.82
Plant, Property, & Equipment, net	0.63	0.95	1.36	1.36	1.35	1.55	1.70
Total Noncurrent Assets	3.30	3.31	5.57	5.17	4.72	4.47	4.17
Intangible Assets	-	-	-	0.97	0.89	0.76	0.61
Other Noncurrent Operating Assets	3.30	3.31	5.57	4.20	3.83	3.72	3.56
Total Liabilities & Shareholders' Equity	58	50	48	44	54	53	40
Total Liabilities	18	18	20	20	19	20	11
Total Current Liabilities	6.10	6.05	6.20	5.59	15	17	7.55
Accounts Payable	1.39	1.35	1.27	0.79	0.84	0.82	0.96
Accrued Expenses	1.25	1.40	1.37	0.95	0.99	1.30	1.18
Current Deferred Revenue	0.74	1.28	0.72	1.18	1.23	1.08	1.25
Current Employee Benefit Liabilities	2.19	1.45	2.34	2.29	1.63	3.00	3.64
Other Current Liabilities	0.54	0.57	0.49	0.38	0.50	0.52	0.54
Total Noncurrent Liabilities	12	12	14	14	3.90	3.75	3.64
Long-Term Debt	9.88	9.91	9.92	9.94	0.00	0.00	0.00
Noncurrent Deferred Revenue	0.35	0.32	0.25	0.52	0.46	0.45	0.48
Other Noncurrent Operating Liabilities	1.54	1.39	3.86	3.70	3.44	3.30	3.16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	40	33	27	24	35	32	29
Total Preferred & Common Equity	40	33	27	24	35	32	29
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	40	33	27	24	35	32	29
Common Stock	186	189	190	192	211	213	215
Retained Earnings	-146	-156	-163	-168	-177	-181	-186

This table displays calculated financial ratios and metrics derived from ClearPoint Neuro's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	26.09%	16.56%	31.04%
EBITDA Growth	-25.00%	-33.23%	15.32%
EBIT Growth	-21.71%	-37.25%	11.85%
NOPAT Growth	-22.12%	-37.44%	12.03%
Net Income Growth	-14.05%	-34.40%	14.37%
EPS Growth	1.45%	-32.35%	22.22%
Operating Cash Flow Growth	-27.33%	15.14%	34.77%
Free Cash Flow Firm Growth	-57.05%	11.13%	22.76%
Invested Capital Growth	105.74%	-14.09%	-33.79%
Revenue Q/Q Growth	4.54%	7.33%	3.16%
EBITDA Q/Q Growth	-4.45%	0.75%	-5.35%
EBIT Q/Q Growth	-3.21%	-1.07%	-4.98%
NOPAT Q/Q Growth	-3.07%	-1.07%	-4.76%
Net Income Q/Q Growth	-1.46%	-1.07%	-4.23%
EPS Q/Q Growth	4.23%	0.00%	-2.94%
Operating Cash Flow Q/Q Growth	2.92%	12.14%	-0.83%
Free Cash Flow Firm Q/Q Growth	0.60%	9.63%	-1.74%
Invested Capital Q/Q Growth	-0.05%	-17.60%	-28.85%
Profitability Metrics	-	-	-
Gross Margin	65.84%	56.83%	60.92%
EBITDA Margin	-76.91%	-87.91%	-56.81%
Operating Margin	-79.47%	-93.70%	-62.91%
EBIT Margin	-79.58%	-93.70%	-63.03%
Profit (Net Income) Margin	-79.97%	-92.21%	-60.25%
Tax Burden Percent	100.00%	100.13%	100.00%
Interest Burden Percent	100.50%	98.28%	95.59%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-165.60%	-181.93%	-208.37%
ROIC Less NNEP Spread (ROIC-NNEP)	-151.68%	-150.66%	-177.78%
Return on Net Nonoperating Assets (RNNOA)	127.24%	105.84%	127.13%
Return on Equity (ROE)	-38.37%	-76.09%	-81.24%
Cash Return on Invested Capital (CROIC)	-234.77%	-166.77%	-167.71%
Operating Return on Assets (OROA)	-27.02%	-45.74%	-48.35%
Return on Assets (ROA)	-27.15%	-45.01%	-46.22%
Return on Common Equity (ROCE)	-38.37%	-76.09%	-81.24%
Return on Equity Simple (ROE_SIMPLE)	-44.56%	-104.33%	-74.50%
Net Operating Profit after Tax (NOPAT)	-11	-16	-14
NOPAT Margin	-55.63%	-65.59%	-44.03%
Net Nonoperating Expense Percent (NNEP)	-13.92%	-31.27%	-30.59%
Return On Investment Capital (ROIC_SIMPLE)	-	-50.49%	-54.44%
Cost of Revenue to Revenue	34.16%	43.17%	39.08%
SG&A Expenses to Revenue	46.77%	49.08%	38.22%
R&D to Revenue	53.01%	48.88%	39.48%
Operating Expenses to Revenue	145.31%	150.53%	123.82%
Earnings before Interest and Taxes (EBIT)	-16	-22	-20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-16	-21	-18
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	5.64	7.90	16.71
Price to Tangible Book Value (P/TBV)	5.64	8.30	17.03
Price to Revenue (P/Rev)	10.12	6.98	13.52
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.41	19.29	76.47
Enterprise Value to Revenue (EV/Rev)	8.78	6.43	12.88
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.27	0.47	0.00
Long-Term Debt to Equity	0.27	0.47	0.00
Financial Leverage	-0.84	-0.70	-0.72
Leverage Ratio	1.41	1.69	1.76
Compound Leverage Factor	1.42	1.66	1.68
Debt to Total Capital	21.15%	31.97%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	21.15%	31.97%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	78.85%	68.03%	100.00%
Debt to EBITDA	-0.63	-0.47	0.00
Net Debt to EBITDA	1.75	0.63	0.00
Long-Term Debt to EBITDA	-0.63	-0.47	0.00
Debt to NOPAT	-0.87	-0.63	0.00
Net Debt to NOPAT	2.41	0.84	0.00
Long-Term Debt to NOPAT	-0.87	-0.63	0.00
Altman Z-Score	3.27	-1.36	11.45
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.54	4.87	3.22
Quick Ratio	5.92	3.55	2.40
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-14	-11
Operating Cash Flow to CapEx	-6,390.12%	-1,913.53%	-3,254.55%
Free Cash Flow to Firm to Interest Expense	-200.09	0.00	0.00
Operating Cash Flow to Interest Expense	-199.59	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-202.72	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.34	0.49	0.77
Accounts Receivable Turnover	8.22	8.15	7.92
Inventory Turnover	0.99	1.20	1.66
Fixed Asset Turnover	30.56	21.83	18.50
Accounts Payable Turnover	20.09	31.10	14.16
Days Sales Outstanding (DSO)	44.42	44.77	46.07
Days Inventory Outstanding (DIO)	370.23	303.80	219.78
Days Payable Outstanding (DPO)	18.17	11.74	25.78
Cash Conversion Cycle (CCC)	396.47	336.83	240.07
Capital & Investment Metrics	-	-	-
Invested Capital	9.29	7.98	5.29
Invested Capital Turnover	2.98	2.77	4.73
Increase / (Decrease) in Invested Capital	4.78	-1.31	-2.70
Enterprise Value (EV)	180	154	404
Market Capitalization	208	167	424
Book Value per Share	$1.50	$0.86	$0.92
Tangible Book Value per Share	$1.50	$0.82	$0.90
Total Capital	47	31	25
Total Debt	9.89	9.95	0.00
Total Long-Term Debt	9.89	9.95	0.00
Net Debt	-28	-13	-20
Capital Expenditures (CapEx)	0.25	0.72	0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6.90	5.60	2.91
Debt-free Net Working Capital (DFNWC)	44	29	23
Net Working Capital (NWC)	44	29	23
Net Nonoperating Expense (NNE)	5.00	6.38	5.09
Net Nonoperating Obligations (NNO)	-28	-13	-20
Total Depreciation and Amortization (D&A)	0.55	1.39	1.95
Debt-free, Cash-free Net Working Capital to Revenue	33.59%	23.39%	9.26%
Debt-free Net Working Capital to Revenue	216.01%	119.98%	73.30%
Net Working Capital to Revenue	216.01%	119.98%	73.30%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.68)	($0.90)	($0.70)
Adjusted Weighted Average Basic Shares Outstanding	24.18M	24.61M	27.03M
Adjusted Diluted Earnings per Share	($0.68)	($0.90)	($0.70)
Adjusted Weighted Average Diluted Shares Outstanding	24.18M	24.61M	27.03M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	24.61M	26.98M	27.63M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-16	-14
Normalized NOPAT Margin	-55.63%	-65.59%	-44.03%
Pre Tax Income Margin	-79.97%	-92.09%	-60.25%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-201.90	0.00	0.00
NOPAT to Interest Expense	-141.14	0.00	0.00
EBIT Less CapEx to Interest Expense	-205.02	0.00	0.00
NOPAT Less CapEx to Interest Expense	-144.26	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from ClearPoint Neuro's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	12.51%	20.83%	7.99%	14.42%	11.97%	31.62%	40.60%	32.07%	40.96%	14.11%
EBITDA Growth	-6.58%	-17.12%	-52.09%	-71.87%	-18.24%	3.61%	31.58%	37.74%	-4.62%	-20.48%
EBIT Growth	-2.08%	-12.12%	-48.53%	-69.67%	-28.19%	-5.30%	25.62%	33.63%	-5.84%	-19.25%
NOPAT Growth	0.24%	-12.23%	-47.83%	-69.62%	-29.04%	-5.30%	25.93%	33.54%	-5.62%	-19.08%
Net Income Growth	4.82%	-5.69%	-41.68%	-63.89%	-26.95%	-5.34%	26.08%	37.49%	-3.43%	-16.61%
EPS Growth	16.67%	14.29%	-35.29%	-61.11%	-33.33%	0.00%	30.43%	44.83%	10.00%	-11.11%
Operating Cash Flow Growth	-16.87%	13.71%	-33.05%	-1.89%	53.37%	61.86%	32.39%	47.43%	33.24%	-6.33%
Free Cash Flow Firm Growth	-123.79%	-111.01%	-76.94%	-26.98%	51.48%	74.88%	84.09%	79.35%	64.35%	38.25%
Invested Capital Growth	127.73%	105.74%	81.53%	43.97%	4.21%	-14.09%	-14.48%	-14.73%	-23.32%	-33.79%
Revenue Q/Q Growth	-1.04%	0.54%	5.01%	9.52%	-3.16%	18.19%	12.17%	2.87%	3.36%	-4.32%
EBITDA Q/Q Growth	5.18%	-17.36%	-24.40%	-24.15%	34.77%	4.33%	11.78%	-12.98%	-9.61%	-10.18%
EBIT Q/Q Growth	9.13%	-16.99%	-28.06%	-24.64%	31.35%	3.90%	9.62%	-11.21%	-9.48%	-8.28%
NOPAT Q/Q Growth	9.73%	-17.76%	-27.81%	-24.84%	31.33%	3.90%	10.09%	-12.01%	-9.14%	-8.35%
Net Income Q/Q Growth	11.97%	-15.76%	-27.91%	-25.73%	31.81%	3.95%	10.24%	-6.32%	-12.84%	-8.28%
EPS Q/Q Growth	16.67%	-20.00%	-27.78%	-26.09%	31.03%	10.00%	11.11%	0.00%	-12.50%	-11.11%
Operating Cash Flow Q/Q Growth	22.67%	20.43%	-85.32%	10.65%	64.61%	34.91%	-228.49%	30.52%	55.06%	-3.67%
Free Cash Flow Firm Q/Q Growth	-20.26%	-0.42%	-11.69%	5.85%	54.05%	48.02%	29.24%	-22.18%	20.68%	9.96%
Invested Capital Q/Q Growth	23.16%	-0.05%	15.72%	1.07%	-10.86%	-17.60%	15.20%	0.77%	-19.84%	-28.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.49%	65.06%	58.94%	52.54%	56.80%	58.93%	59.24%	63.48%	59.68%	61.28%
EBITDA Margin	-73.30%	-85.56%	-101.36%	-114.91%	-77.40%	-62.66%	-49.33%	-54.17%	-57.45%	-66.16%
Operating Margin	-73.75%	-86.37%	-105.14%	-119.85%	-84.99%	-69.10%	-55.39%	-60.31%	-63.68%	-72.11%
EBIT Margin	-74.23%	-86.37%	-105.34%	-119.88%	-84.99%	-69.10%	-55.73%	-60.24%	-63.81%	-72.22%
Profit (Net Income) Margin	-73.61%	-84.75%	-103.24%	-118.52%	-83.46%	-67.83%	-54.27%	-56.10%	-61.24%	-69.31%
Tax Burden Percent	100.00%	99.82%	100.00%	100.00%	100.25%	100.37%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.16%	98.30%	98.01%	98.86%	97.96%	97.79%	97.39%	93.11%	95.97%	95.97%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-151.72%	-179.99%	-184.95%	-197.75%	-139.89%	-134.17%	-101.70%	-117.71%	-158.50%	-238.87%
ROIC Less NNEP Spread (ROIC-NNEP)	-148.51%	-176.49%	-179.72%	-189.79%	-133.75%	-127.68%	-96.68%	-112.18%	-150.98%	-230.08%
Return on Net Nonoperating Assets (RNNOA)	124.86%	148.05%	141.46%	140.03%	94.06%	89.69%	67.97%	74.25%	102.31%	164.53%
Return on Equity (ROE)	-26.86%	-31.94%	-43.50%	-57.72%	-45.83%	-44.48%	-33.73%	-43.47%	-56.19%	-74.35%
Cash Return on Invested Capital (CROIC)	-243.77%	-234.77%	-210.55%	-196.51%	-167.91%	-166.77%	-131.53%	-113.25%	-127.78%	-167.71%
Operating Return on Assets (OROA)	-23.08%	-29.32%	-39.41%	-48.23%	-37.35%	-33.73%	-28.07%	-33.75%	-46.22%	-55.39%
Return on Assets (ROA)	-22.89%	-28.77%	-38.62%	-47.69%	-36.68%	-33.11%	-27.34%	-31.42%	-44.35%	-53.16%
Return on Common Equity (ROCE)	-26.86%	-31.94%	-43.50%	-57.72%	-45.83%	-44.48%	-33.73%	-43.47%	-56.19%	-74.35%
Return on Equity Simple (ROE_SIMPLE)	-40.62%	0.00%	-55.51%	-76.01%	-90.71%	0.00%	-59.64%	-55.96%	-62.57%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.66	-3.13	-4.00	-4.99	-3.43	-3.29	-2.96	-3.32	-3.62	-3.92
NOPAT Margin	-51.62%	-60.46%	-73.59%	-83.89%	-59.49%	-48.37%	-38.77%	-42.22%	-44.58%	-50.48%
Net Nonoperating Expense Percent (NNEP)	-3.20%	-3.50%	-5.23%	-7.95%	-6.14%	-6.50%	-5.02%	-5.54%	-7.52%	-8.79%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-10.58%	-	-	-	-15.45%
Cost of Revenue to Revenue	28.51%	34.94%	41.06%	47.46%	43.20%	41.07%	40.76%	36.52%	40.32%	38.72%
SG&A Expenses to Revenue	46.60%	45.92%	54.45%	53.41%	50.33%	39.94%	37.19%	35.29%	38.85%	41.55%
R&D to Revenue	51.57%	56.59%	55.64%	60.59%	42.16%	38.94%	34.36%	39.70%	40.82%	42.88%
Operating Expenses to Revenue	145.24%	151.43%	164.07%	172.39%	141.79%	128.03%	114.62%	123.78%	123.36%	133.39%
Earnings before Interest and Taxes (EBIT)	-3.82	-4.47	-5.72	-7.13	-4.90	-4.71	-4.26	-4.73	-5.18	-5.61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.77	-4.43	-5.51	-6.84	-4.46	-4.27	-3.77	-4.26	-4.67	-5.14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.36	5.64	6.38	6.49	5.12	7.90	5.30	4.60	10.67	16.71
Price to Tangible Book Value (P/TBV)	6.36	5.64	6.38	6.49	5.34	8.30	5.44	4.71	10.90	17.03
Price to Revenue (P/Rev)	12.90	10.12	9.91	8.20	5.53	6.98	7.01	5.27	10.17	13.52
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	24.00	19.41	17.29	14.86	11.25	19.29	17.19	13.48	38.74	76.47
Enterprise Value to Revenue (EV/Rev)	11.35	8.78	8.87	7.44	4.88	6.43	6.04	4.45	9.46	12.88
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.25	0.27	0.30	0.36	0.41	0.47	0.29	0.31	0.00	0.00
Long-Term Debt to Equity	0.25	0.27	0.30	0.36	0.41	0.47	0.00	0.00	0.00	0.00
Financial Leverage	-0.84	-0.84	-0.79	-0.74	-0.70	-0.70	-0.70	-0.66	-0.68	-0.72
Leverage Ratio	1.51	1.41	1.43	1.54	1.59	1.69	1.55	1.68	1.58	1.76
Compound Leverage Factor	1.49	1.39	1.40	1.52	1.56	1.65	1.51	1.57	1.52	1.69
Debt to Total Capital	19.85%	21.15%	23.32%	26.58%	29.20%	31.97%	22.37%	23.70%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.37%	23.70%	0.00%	0.00%
Long-Term Debt to Total Capital	19.85%	21.15%	23.32%	26.58%	29.20%	31.97%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	80.15%	78.85%	76.68%	73.42%	70.80%	68.03%	77.63%	76.30%	100.00%	100.00%
Debt to EBITDA	-0.65	-0.63	-0.56	-0.48	-0.47	-0.47	-0.52	-0.60	0.00	0.00
Net Debt to EBITDA	2.02	1.75	1.23	0.81	0.68	0.63	1.31	1.36	0.00	0.00
Long-Term Debt to EBITDA	-0.65	-0.63	-0.56	-0.48	-0.47	-0.47	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.89	-0.87	-0.78	-0.67	-0.64	-0.63	-0.68	-0.77	0.00	0.00
Net Debt to NOPAT	2.76	2.41	1.72	1.12	0.93	0.84	1.73	1.76	0.00	0.00
Long-Term Debt to NOPAT	-0.89	-0.87	-0.78	-0.67	-0.64	-0.63	0.00	0.00	0.00	0.00
Altman Z-Score	6.10	3.98	3.70	1.32	-0.60	0.01	2.12	0.44	11.24	12.64
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.83	7.54	7.60	6.56	6.68	4.87	3.14	2.79	4.54	3.22
Quick Ratio	7.20	5.92	5.68	4.72	4.79	3.55	2.50	2.18	3.37	2.40
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-7.87	-7.90	-8.83	-8.31	-3.82	-1.99	-1.40	-1.72	-1.36	-1.23
Operating Cash Flow to CapEx	-5,582.61%	-7,858.97%	-4,115.94%	-1,571.21%	-764.26%	-5,566.67%	0.00%	0.00%	-9,991.67%	-472.62%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.34	0.37	0.40	0.44	0.49	0.50	0.56	0.72	0.77
Accounts Receivable Turnover	6.59	8.22	8.52	7.06	7.65	8.15	10.08	8.95	9.66	7.92
Inventory Turnover	1.03	0.99	0.96	1.05	1.08	1.20	1.26	1.31	1.50	1.66
Fixed Asset Turnover	36.44	30.56	25.28	21.18	22.50	21.83	22.79	19.32	19.95	18.50
Accounts Payable Turnover	5.82	20.09	6.43	5.82	8.60	31.10	10.22	10.76	13.83	14.16
Days Sales Outstanding (DSO)	55.42	44.42	42.86	51.69	47.71	44.77	36.20	40.79	37.78	46.07
Days Inventory Outstanding (DIO)	354.19	370.23	380.63	347.10	337.04	303.80	288.90	279.09	242.90	219.78
Days Payable Outstanding (DPO)	62.69	18.17	56.75	62.77	42.46	11.74	35.71	33.93	26.40	25.78
Cash Conversion Cycle (CCC)	346.93	396.47	366.74	336.02	342.28	336.83	289.40	285.96	254.28	240.07
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	9.30	9.29	11	11	9.69	7.98	9.20	9.27	7.43	5.29
Invested Capital Turnover	2.94	2.98	2.51	2.36	2.35	2.77	2.62	2.79	3.56	4.73
Increase / (Decrease) in Invested Capital	5.21	4.78	4.83	3.32	0.39	-1.31	-1.56	-1.60	-2.26	-2.70
Enterprise Value (EV)	223	180	186	161	109	154	158	125	288	404
Market Capitalization	254	208	208	178	123	167	183	148	309	424
Book Value per Share	$1.63	$1.50	$1.32	$1.12	$0.98	$0.86	$1.28	$1.17	$1.05	$0.92
Tangible Book Value per Share	$1.63	$1.50	$1.32	$1.12	$0.94	$0.82	$1.25	$1.14	$1.03	$0.90
Total Capital	50	47	42	37	34	31	45	42	29	25
Total Debt	9.88	9.89	9.91	9.92	9.94	9.95	9.96	9.98	0.00	0.00
Total Long-Term Debt	9.88	9.89	9.91	9.92	9.94	9.95	0.00	0.00	0.00	0.00
Net Debt	-31	-28	-22	-17	-14	-13	-25	-23	-22	-20
Capital Expenditures (CapEx)	0.07	0.04	0.14	0.32	0.24	0.02	0.00	0.00	0.01	0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.26	6.90	8.20	8.05	7.38	5.60	7.02	7.00	5.20	2.91
Debt-free Net Working Capital (DFNWC)	48	44	40	35	32	29	42	40	27	23
Net Working Capital (NWC)	48	44	40	35	32	29	32	30	27	23
Net Nonoperating Expense (NNE)	1.13	1.26	1.61	2.06	1.38	1.32	1.18	1.09	1.35	1.46
Net Nonoperating Obligations (NNO)	-31	-28	-22	-17	-14	-13	-25	-23	-22	-20
Total Depreciation and Amortization (D&A)	0.05	0.04	0.22	0.30	0.44	0.44	0.49	0.48	0.52	0.47
Debt-free, Cash-free Net Working Capital to Revenue	36.92%	33.59%	39.12%	37.07%	33.06%	23.39%	26.85%	24.92%	17.10%	9.26%
Debt-free Net Working Capital to Revenue	242.73%	216.01%	190.57%	159.01%	142.13%	119.98%	161.99%	141.94%	88.00%	73.30%
Net Working Capital to Revenue	242.73%	216.01%	190.57%	159.01%	142.13%	119.98%	123.90%	106.39%	88.00%	73.30%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.15)	($0.18)	($0.23)	($0.29)	($0.20)	($0.18)	($0.16)	($0.16)	($0.18)	($0.20)
Adjusted Weighted Average Basic Shares Outstanding	24.50M	24.18M	24.58M	24.58M	24.63M	24.61M	25.45M	27.47M	27.59M	27.03M
Adjusted Diluted Earnings per Share	($0.15)	($0.18)	($0.23)	($0.29)	($0.20)	($0.18)	($0.16)	($0.16)	($0.18)	($0.20)
Adjusted Weighted Average Diluted Shares Outstanding	24.50M	24.18M	24.58M	24.58M	24.63M	24.61M	25.45M	27.47M	27.59M	27.03M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	24.55M	24.61M	24.58M	24.64M	24.62M	26.98M	27.42M	27.60M	27.58M	27.63M
Normalized Net Operating Profit after Tax (NOPAT)	-2.66	-3.13	-4.00	-4.99	-3.43	-3.29	-2.96	-3.32	-3.62	-3.92
Normalized NOPAT Margin	-51.62%	-60.46%	-73.59%	-83.89%	-59.49%	-48.37%	-38.77%	-42.22%	-44.58%	-50.48%
Pre Tax Income Margin	-73.61%	-84.91%	-103.24%	-118.52%	-83.25%	-67.58%	-54.27%	-56.10%	-61.24%	-69.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, investor-focused read on ClearPoint Neuro (NASDAQ: CLPT) using the latest quarterly data across the last four years. The company shows revenue growth and margin improvement but remains unprofitable with ongoing cash burn. Financing activity in 2024 helped bolster liquidity, while the balance sheet reflects a sizable accumulated deficit funded by equity.

Q4 2024 revenue rose to about $7.77 million with gross margin around 61%, up modestly from Q4 2023 (gross profit ~ $4.76 million on revenue ~ $7.77 million).
Equity financing in 2024 boosted liquidity, including a notable common-equity issuance in Q1 2024 that raised roughly $16.2 million, helping fund ongoing operations.
Cash balances fluctuated but remained supported by financing activity, with balances in the 20s–30s millions range at times in 2024 (e.g., ~$21.6 million in Q3 2024 and ~$35.3 million at Q1 2024).
Long-term debt remained effectively zero across the reported periods, indicating liquidity has been funded through equity rather than debt.
Total assets and liabilities vary by quarter but CLPT maintains a modest asset base relative to equity, with a balance sheet profile typical of a growth-stage biotech.
Net income remained negative in Q4 2024 at about −$5.39 million, continuing a multi-quarter loss trend despite top-line growth.
Operating expenses remained high (Q4 2024 operating expenses ~ $10.37 million), contributing to a sizable operating loss for the quarter.
Operating cash flow was negative in all 2024 quarters, including about −$1.24 million in Q4 2024, signaling ongoing cash burn from core operations.
Retained earnings stayed deeply negative across periods, reflecting a long-running accumulated deficit despite equity-funded capital increases.
Diluted earnings per share were negative in Q4 2024 (about −$0.20), consistent with the ongoing net losses per share.

05/08/26 10:18 PM ETAI Generated. May Contain Errors.

ClearPoint Neuro Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ClearPoint Neuro's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

ClearPoint Neuro's net income appears to be on an upward trend, with a most recent value of -$18.91 million in 2024, rising from -$16.44 million in 2022. The previous period was -$22.09 million in 2023. See where experts think ClearPoint Neuro is headed by visiting ClearPoint Neuro's forecast page.

ClearPoint Neuro's total operating income in 2024 was -$19.75 million, based on the following breakdown:

Total Gross Profit: $19.12 million
Total Operating Expenses: $38.87 million

Over the last 2 years, ClearPoint Neuro's total revenue changed from $20.55 million in 2022 to $31.39 million in 2024, a change of 52.7%.

ClearPoint Neuro's total liabilities were at $13.80 million at the end of 2024, a 35.8% decrease from 2023, and a 25.8% decrease since 2022.

In the past 2 years, ClearPoint Neuro's cash and equivalents has ranged from $20.10 million in 2024 to $27.62 million in 2022, and is currently $20.10 million as of their latest financial filing in 2024.

Over the last 2 years, ClearPoint Neuro's book value per share changed from 1.50 in 2022 to 0.92 in 2024, a change of -38.7%.

Related Companies

Financial statements for NASDAQ:CLPT last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Financials

Financials Breakdown Chart

Key Financial Trends

ClearPoint Neuro Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Financials

Annual Income Statements for ClearPoint Neuro

Quarterly Income Statements for ClearPoint Neuro

Annual Cash Flow Statements for ClearPoint Neuro

Quarterly Cash Flow Statements for ClearPoint Neuro

Annual Balance Sheets for ClearPoint Neuro

Quarterly Balance Sheets for ClearPoint Neuro

Annual Metrics And Ratios for ClearPoint Neuro

Quarterly Metrics And Ratios for ClearPoint Neuro

Financials Breakdown Chart

Key Financial Trends

ClearPoint Neuro Financials - Frequently Asked Questions

When does ClearPoint Neuro's financial year end?

How has ClearPoint Neuro's net income changed over the last 2 years?

What is ClearPoint Neuro's operating income?

How has ClearPoint Neuro's revenue changed over the last 2 years?

How much debt does ClearPoint Neuro have?

How much cash does ClearPoint Neuro have?

How has ClearPoint Neuro's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools